About NeoGenomics
NeoGenomics is a company based in Fort Myers (United States) founded in 2002. It operates as a Professional Services, and Data-as-a-Service. The company has 2,200 employees as of December 31, 2024. NeoGenomics has completed 7 acquisitions, including GE Healthcare, Genoptix and Inivata. NeoGenomics offers products and services including PanTracer Tissue, Paletrra, and Comprehensive Genomic Profiling. NeoGenomics operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
- Headquarter Fort Myers, United States
- Employees 2200 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Neogenomics, Inc.
-
Annual Revenue
$660.57 M11.65as on Dec 31, 2024
-
Net Profit
$-78.73 M10.51as on Dec 31, 2024
-
EBITDA
$852 K103.54as on Dec 31, 2024
-
Latest Funding Round
$345 M (USD), Post-IPO
Jan 20, 2021
-
Investors
-
Employee Count
2200
as on Dec 31, 2024
-
Investments & Acquisitions
GE Healthcare
& 6 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of NeoGenomics
NeoGenomics is a publicly listed company on the NASDAQ with ticker symbol NEO in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of NeoGenomics
NeoGenomics offers a comprehensive portfolio of products and services, including PanTracer Tissue, Paletrra, and Comprehensive Genomic Profiling. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Comprehensive genomic profiling for solid tumor diagnostics is provided.
Spatial proteomics insights for tissue analysis are delivered effectively.
Advanced genomic profiling for cancer diagnostics is offered here.
Unlock access to complete
Unlock access to complete
Funding Insights of NeoGenomics
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $345.0M
-
First Round
First Round
(30 Mar 2009)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Post-IPO - NeoGenomics | Valuation |
investors |
|
| Jun, 2019 | Amount | Debt – Conventional - NeoGenomics | Valuation |
investors |
|
| Mar, 2009 | Amount | Post-IPO - NeoGenomics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by NeoGenomics
NeoGenomics has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include GE Healthcare, Genoptix and Inivata. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Liquid biopsy platform for cancer detection is developed.
|
2014 | ||||
|
Pathology laboratory services are provided independently in the United States.
|
2009 | ||||
|
Precision medicine platform is provided for oncologists' decision support.
|
2009 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - NeoGenomics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Neogenomics Comparisons
Competitors of NeoGenomics
NeoGenomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are provided.
|
|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Health risks are identified through online genetic and diagnostic testing.
|
|
| domain | founded_year | HQ Location |
Genomic sequencing and diagnosis software is provided for healthcare.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Neogenomics
Frequently Asked Questions about NeoGenomics
When was NeoGenomics founded?
NeoGenomics was founded in 2002 and raised its 1st funding round 7 years after it was founded.
Where is NeoGenomics located?
NeoGenomics is headquartered in Fort Myers, United States. It is registered at Fort Myers, Florida, United States.
How many employees does NeoGenomics have?
As of Dec 31, 2024, the latest employee count at NeoGenomics is 2,200.
What is the annual revenue of NeoGenomics?
Annual revenue of NeoGenomics is $660.57M as on Dec 31, 2024.
What does NeoGenomics do?
NeoGenomics Laboratories is focused on precision oncology diagnostics, offering a wide range of testing solutions for solid tumors and hematologic cancers. Over 500 tests are provided, including molecular testing, immunohistochemistry, flow cytometry, and next-generation sequencing. Services are tailored for oncologists, biopharma partners, and patients, supporting personalized care, drug development, and clinical trials. The company contributes to cancer research through real-world evidence and genomic insights. Testing portfolios cover lung, breast, colorectal, and other cancer types, ensuring alignment with the latest guidelines and evidence.
Who are the top competitors of NeoGenomics?
NeoGenomics's top competitors include Guardant Health, Foundation Medicine and Personalis.
What products or services does NeoGenomics offer?
NeoGenomics offers PanTracer Tissue, Paletrra, and Comprehensive Genomic Profiling.
Is NeoGenomics publicly traded?
Yes, NeoGenomics is publicly traded on NASDAQ under the ticker symbol NEO.
How many acquisitions has NeoGenomics made?
NeoGenomics has made 7 acquisitions, including GE Healthcare, Genoptix, and Inivata.
What is NeoGenomics's ticker symbol?
The ticker symbol of NeoGenomics is NEO on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.